Tracy Saxton, PhD, MBA
Chief Business Officer
Dr. Saxton has held investment positions with Pivotal bioVenture Partners, the Roche Venture Fund and SV Life Sciences Advisers. Dr. Saxton has served on the Board of Directors of SutroVax, Iterum Therapeutics, Entasis Therapeutics, Millendo Therapeutics, Lumos Therapeutics, Mission Therapeutics and PanOptica. Dr. Saxton previously held positions at Tularik (acquired by Amgen) and Threshold Pharmaceuticals. She began her career as a drug discovery scientist and moved to leadership roles in Regulatory Affairs, Clinical Development and Project Management. Dr. Saxton earned her PhD in Medical Genetics from the University of Toronto, her MBA from Columbia University.